Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Analysts at William Blair lowered their Q2 2017 earnings estimates for Collegium Pharmaceutical in a research report issued to clients and investors on Tuesday. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will post earnings per share of ($0.76) for the quarter, down from their prior forecast of ($0.74). William Blair also issued estimates for Collegium Pharmaceutical’s Q3 2017 earnings at ($0.74) EPS, Q4 2017 earnings at ($0.71) EPS, FY2017 earnings at ($3.01) EPS, FY2018 earnings at ($2.49) EPS and FY2019 earnings at ($1.32) EPS.
Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.19. The company had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $3.55 million. COPYRIGHT VIOLATION NOTICE: This piece was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/07/21/q2-2017-eps-estimates-for-collegium-pharmaceutical-inc-lowered-by-william-blair-nasdaqcoll.html.
A number of other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. ValuEngine raised shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Janney Montgomery Scott reissued a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, June 12th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, June 9th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $22.00 price target (down previously from $24.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 11th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the company. Collegium Pharmaceutical currently has a consensus rating of “Hold” and an average target price of $22.83.
Collegium Pharmaceutical (NASDAQ COLL) opened at 12.39 on Thursday. The stock has a 50 day moving average of $11.57 and a 200 day moving average of $12.38. The stock’s market cap is $364.98 million. Collegium Pharmaceutical has a 12-month low of $7.37 and a 12-month high of $20.55.
In other news, insider Paul Brannelly acquired 10,000 shares of the firm’s stock in a transaction on Friday, May 12th. The shares were bought at an average price of $9.18 per share, for a total transaction of $91,800.00. Following the acquisition, the insider now owns 110,227 shares of the company’s stock, valued at approximately $1,011,883.86. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 25.76% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Macquarie Group Ltd. purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter worth $127,000. American International Group Inc. raised its position in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares during the last quarter. Nationwide Fund Advisors raised its position in shares of Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 1,422 shares during the last quarter. Credit Suisse AG raised its position in shares of Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares during the last quarter. Finally, UBS Group AG raised its position in shares of Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 10,174 shares during the last quarter. Institutional investors own 82.30% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.